title: cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers.
abstract: The acquisition of epithelial-neuroendocrine differentiation (ND) is a peculiarity of human advanced, androgen-independent, prostate cancers. The HOX genes are a network of transcription factors controlling embryonal development and playing an important role in crucial adult eukaryotic cell functions. The molecular organization of this 39-gene network is unique in the genome and probably acts by regulating phenotype cell identity. The expression patterns of the HOX gene network in human prostate cell phenotypes, representing different stages of prostate physiology and prostate cancer progression, make it possible to discriminate between different human prostate cell lines and to identify loci and paralogous groups harboring the HOX genes mostly involved in prostate organogenesis and cancerogenesis. Exposure of prostate epithelial phenotypes to cAMP alters the expression of lumbo-sacral HOX D genes located on the chromosomal region 2q31-33 where the cAMP effector genes CREB1, CREB2, and cAMP-GEFII are present. Interestingly, this same chromosomal area harbors: (i) a global cis-regulatory DNA control region able to coordinate the expression of HOX D and contiguous phylogenetically unrelated genes; (ii) a prostate specific ncRNA gene associated with high-risk prostate cancer (PCGEM1); (iii) a series of neurogenic-related genes involved with epithelial-neuronal cell conversion. We report the expression of neurexin 1, Neuro D1, dlx1, and dlx2 in untreated and cAMP treated epithelial prostate cells. The in vivo expression of Neuro D1 in human advanced prostate cancers correlate with the state of tumor differentiation as measured by Gleason score. Thus, we suggest that the chromosomal area 2q 31-33 might be involved in the epithelial-ND characteristic of human advanced prostate cancers.
authors.affiliation: Department of Clinical and Experimental Medical, Federico II University Medical School, Naples, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Cantile
authors.forename: A
authors.initials: A
authors.lastname: Kisslinger
authors.forename: L
authors.initials: L
authors.lastname: Cindolo
authors.forename: G
authors.initials: G
authors.lastname: Schiavo
authors.forename: V
authors.initials: V
authors.lastname: D'Antò
authors.forename: R
authors.initials: R
authors.lastname: Franco
authors.forename: V
authors.initials: V
authors.lastname: Altieri
authors.forename: A
authors.initials: A
authors.lastname: Gallo
authors.forename: A
authors.initials: A
authors.lastname: Villacci
authors.forename: D
authors.initials: D
authors.lastname: Tramontano
authors.forename: C
authors.initials: C
authors.lastname: Cillo
mesh_terms: D003994:Bucladesine / Q000494:pharmacology*; D018929:Cell Culture Techniques; D002454:Cell Differentiation / Q000187:drug effects*; D002460:Cell Line; D045744:Cell Line, Tumor; D002874:Chromosome Mapping; D002889:Chromosomes, Human, Pair 2; D018450:Disease Progression; D015870:Gene Expression / Q000187:drug effects*; D005801:Genes, Homeobox; D018398:Homeodomain Proteins / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009490:Neurosecretory Systems / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D018398:Homeodomain Proteins; D003994:Bucladesine